Woman
dies from brain haemorrhage in Japan days after vaccine,
but link uncertain
Send a link to a friend
[March 02, 2021]
TOKYO (Reuters) - A Japanese a woman in her
60s died from a brain haemorrhage three days after receiving a Pfizer
coronavirus vaccination, the health ministry said on Tuesday, adding
that there may not be a link between the two.
|
The woman was vaccinated on Friday and is suspected to have suffered
a brain haemorrhage three days later, on Monday, it said. It was
Japan's first reported death following a vaccination.
"The brain haemorrhage that is suspected as a cause is relatively
common among people from their 40s to their 60s, and at this time,
based on examples overseas, there does not seem to be a link between
brain haemorrhages and the coronavirus vaccine," the ministry quoted
Tomohiro Morio, a doctor advising the government, as saying.
"It may be a coincidental case, but there is a need to gather more
information and make an assessment in upcoming working groups."
Pfizer officials in Japan were not immediately available for
comment. Pfizer said in November the efficacy of its vaccine was
consistent across age and ethnic groups, and that there were no
major side effects, a sign that the immunisation could be employed
broadly around the world.
[to top of second column] |
Global health authorities have
praised the fast development of safe and
effective COVID vaccines, but have warned people
with serious underlying health conditions to
take medical advice first.
Japan became the last member of the Group of
Seven leading industrialised nations to begin
its vaccination drive, on Feb. 17.
It has so far received three shipments of
vaccine developed by Pfizer and BioNTech.
Japan officially approved Pfizer's vaccine last
month, the first such approval in the country as
it steps up efforts to tame infections in the
run-up to the Summer Olympics.
(Reporting by Ritsuko Ando; Editing by Andrew
Heavens and Nick Macfie)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
|